Interferon beta-1a - Biopartners GmbH/Rentschler

Drug Profile

Interferon beta-1a - Biopartners GmbH/Rentschler

Alternative Names: Biferonex; HSA-free IFN β-1a; Human serum albumin-free interferon beta

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Rentschler
  • Developer Biopartners GmbH
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 May 2009 BioPartners withdraws the centralised marketing application for interferon beta-1a for Multiple sclerosis in European Union
  • 19 Feb 2009 The CHMP has issued a negative opinion regarding approval of interferon beta-1a for treatment of Multiple sclerosis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top